Superiority of cyclosporin A over PSC-833 in enhancement of VP-16 efficacy in murine tumors in vivo

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 5, 1997, Pages 452-454

  Slater, Lewis M ^a   Sweet, Paula ^a   Stupecky, Marie ^a   Osann, Kathyrn ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cyclosporin A; PSC 833; VP 16

Indexed keywords

CYCLOSPORIN A; ETOPOSIDE; VALSPODAR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKEMIA L 1210; LEWIS CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CYCLOSPORINE; CYCLOSPORINS; DRUG SYNERGISM; ETOPOSIDE; FEMALE; IMMUNOSUPPRESSIVE AGENTS; LEUKEMIA L1210; LUNG NEOPLASMS; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; SURVIVAL RATE; TIME FACTORS;

EID: 0031051713     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050597     Document Type: Article

References (14)

1. Slater LM, Sweet P, Stupecky M, Gupta S ( 1986) Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J Clin Invest 77: 1405-1408
2. Twentyman PR (1992) Cyclosporins as drug resistance modifiers. Biochem Pharmacol 43: 109-117
3. Slater LM, Cho J, Wetzel MW (1991) Cyclosporin A potentiation of VP-16: production of long-term survival in murine acute lymphatic leukemia. Cancer Chemother Pharmacol 31: 53-56
4. Boesch D, Gaveriaux C, Jachez B, Pourtier-Manzanedo A, Bollinger P, Loor F (1991) In vivo circumvention of PU-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res 51: 4226-4233
5. Friche E, Jensen PB, Nissen NI (1992) Comparison of cyclosporin A and SDZ PSC 833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor. Cancer Chemother Pharmacol 30: 235-237
6. Slater LM, Sweet P, Wetzel M, Stupecky M, Osann K (1995) Comparison of cyclosporin A, verapamil, PSC 833 and cremophor EL as enhancing agents of VP-16 in murine lymphoid leukemias. Leuk Res 19: 543-548
7. Sonneveld P, Durie BGM, Lokhorst HM (1992) Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 340: 255-259
8. List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S (1993) Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11: 1652-1660
9. Meador J, Sweet P, Stupecky M, Murray S, Gupta S, Slater LM (1987) Enhancement by cyclosporin A of daunorubicin efficacy in Ehrlich ascites carcinoma and murine hepatoma 129. Cancer Res 47: 6216-6219
10. Chen HSL, DeBoer G, Koren G, Thiessen LL, Thorner PS, Giesbrecht E, Haddad G, Verjee V, Ling V, Gallie BL (1992) Cyclosporin A-modulated chemotherapy with focal therapy: a new approach to retinoblastoma. Proc Am Assoc Cancer Res 35: 359
11. Keller RP, Altermatt HJ, Donatsch P, Zihlmann H, Laissue JA, Hiestand PC (1992) Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP-16-213) enhance in vivo cytostatic activity and toxicity. Int J Cancer 51: 433-438
12. Lum BL, Kaubisch S, Yahanda AM, Alder KM, Jew L, Ehsan MN, Brophy NA, Halsey J, Gosland MD, Sibic BI (1992) Alteration of etopside pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 10: 1635-1642
13. Slater LM, Wetzel M, Cho J, Sweet P (1991) Development of cyclosporin A mediated immunity in L1210 leukemia. Br J Cancer 64: 1098-1102
14. 8 T-lymphocytes. Clin Immunol Immunopathol 75: 239-245